All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Mehdi Hamadani, Medical College of Wisconsin, Milwaukee, US. We asked, CAR-T or stem cell transplant for second-line treatment of aggressive B-cell non-Hodgkin lymphoma (NHL)?
CAR-T or stem cell transplant for second-line treatment of aggressive B-cell NHL?
Hamadani begins by outlining the current treatment approaches, however, he explains the problems faced by high-risk patients and those who relapse early. He goes on to discuss three recent randomized studies investigating alternative treatments to improve outcomes for these patients (TRANSFORM, ZUMA, and BELINDA). Finally, Hamadani addresses how he would apply these findings to his own clinical practice, and makes some recommendations for certain treatment settings.
Which patients with aggressive B-cell NHL do not qualify for CAR-T?
During the 4th European CAR T-cell Meeting the Lymphoma Hub was pleased to speak with, Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain, ES. We asked, Which patients with...
The impact of targeted treatment and immunotherapies on the role of hematopoietic stem cell transplantation in the treatment of blood cancers
Hematopoietic stem cell transplantation (HSCT) has been used for the treatment of different types of blood...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox